NIAID is funding and conducting research on many aspects of antimicrobial (drug) resistance, including basic research on how microbes develop resistance, development of new and faster diagnostics, and clinical trials designed to find new vaccines and treatments effective against drug-resistant microbes.
Through the information offered here, researchers can learn about the science being conducted at NIAID and by NIAID-funded researchers. Researchers seeking funding can access opportunities to further their own research, while NIAID and NIH grantees can find out about available resources outside of specific funding opportunities. Recent publications, active networks, and ways to connect with other researchers are also available.
NIAID is always accepting researcher-initiated applications. Connect with NIAID program officers about potential funding for antimicrobial resistance research.
- Dr. Erica Raterman, Preclinical Services Program Manager, Bacteriology and Mycology Branch, Division of Microbiology and Infectious Diseases
- Dr. Erin Zeituni, Product Development Program Manager, Bacteriology and Mycology Branch, Division of Microbiology and Infectious Diseases
See a list of research initiatives focused exclusively or in part on antimicrobial resistance
Resources for Researchers
NIAID offers resources such as technology for licensing or collaboration, computer applications, and other tools and services developed in its labs to the general scientific community for the advancement of biomedical research.
In addition, NIAID provides a comprehensive suite of resources to assist researchers with product development efforts. These include reagents, preclinical services (such as in vivo and in vitro screening and therapeutic development services), and clinical networks to support trials from Phase I through Phase 4.
Connect With Other Researchers
Researchers at NIAID
Much of the antimicrobial resistance research ongoing at NIAID takes place in these laboratories:
- Frank R. DeLeo, Ph.D., and Michael Otto, Ph.D., Laboratory of Bacteriology (LB)
- Clifton E. Barry III, Ph.D., Laboratory of Clinical Immunology and Microbiology (LCIM)
- Thomas E. Wellems, M.D., Ph.D., Laboratory of Malaria and Vector Research (LMVR)
Antibacterial Resistance Leadership Group (ARLG)
The Antibacterial Resistance Leadership Group (ARLG) is composed of scientific experts from government agencies, academic institutions, and nonprofit and industry groups around the world. The ARLG oversees a clinical research network that conducts studies on important aspects of antimicrobial resistance, including testing novel therapeutics and diagnostics.
The ARLG provides a range of opportunities to address clinical questions in AR to the scientific community including fellowships, early stage investigator seed grants, data use, and industry collaborations.
An issue as complex as antimicrobial resistance requires a comprehensive approach that draws upon not only federal agencies and academic researchers, but also industry, healthcare providers, and individual citizens to advance basic and applied research as well as to support public health efforts.
Read more about some of our partners: